Angiotensin 12 (1-9) Mechanisms, Clinical Value, and Researc

Angiotensin 1/2 (1-9): Mechanisms, Clinical Value, and Research Perspectives in Cardiovascular and Renal Therapeutics

Introduction
Angiotensin 1/2 (1-9) is a bioactive peptide derived from the renin-angiotensin system (RAS), a critical hormonal cascade regulating blood pressure, fluid balance, and cardiovascular homeostasis. Angiotensin (1-9) is generated from angiotensin I through the enzymatic activity of angiotensin-converting enzyme 2 (ACE2), bypassing the classical ACE-mediated conversion to angiotensin II (Santos et al., 2013, Hypertension). Unlike angiotensin II, which is a potent vasoconstrictor and pro-fibrotic agent, angiotensin (1-9) exhibits vasodilatory, anti-fibrotic, and cardioprotective properties, primarily through its interaction with the angiotensin II type 2 receptor (AT2R) (Ocaranza & Jalil, 2012, Hypertension Research).

The molecular mechanism of angiotensin (1-9) involves modulation of vascular tone, inhibition of pathological remodeling, and attenuation of inflammatory responses. These effects are mediated by downstream signaling pathways, including nitric oxide (NO) release, cyclic guanosine monophosphate (cGMP) production, and suppression of transforming growth factor-beta (TGF-β) signaling (Ferreira et al., 2010, Peptides). Given its unique profile, angiotensin (1-9) has emerged as a promising candidate for the treatment of cardiovascular and renal diseases, offering potential advantages over traditional RAS inhibitors.

Clinical Value and Applications
The clinical value of angiotensin (1-9) lies in its multifaceted actions that counteract the deleterious effects of excessive angiotensin II signaling. In preclinical models, angiotensin (1-9) administration has demonstrated efficacy in reducing cardiac hypertrophy, fibrosis, and arrhythmogenesis following myocardial infarction (MI) (Ocaranza et al., 2010, Hypertension). Furthermore, its renoprotective effects have been observed in models of diabetic nephropathy and hypertension-induced renal injury, where angiotensin (1-9) attenuates glomerulosclerosis and proteinuria (Pinheiro et al., 2017, American Journal of Physiology-Renal Physiology).

In addition to cardiovascular and renal indications, angiotensin (1-9) has shown potential in modulating inflammatory responses and oxidative stress, suggesting broader applications in metabolic and inflammatory diseases. Its ability to enhance endothelial function and promote vasodilation positions it as a candidate for adjunctive therapy in resistant hypertension and heart failure, particularly in patients with suboptimal responses to ACE inhibitors or angiotensin receptor blockers (ARBs).

[Related: NSC 693627] Key Challenges and Pain Points Addressed
Current RAS-targeted therapies, such as ACE inhibitors and ARBs, are effective in reducing morbidity and mortality in cardiovascular and renal diseases. However, several challenges persist, including incomplete RAS blockade, adverse effects (e.g., cough, angioedema), and compensatory upregulation of alternative RAS pathways (Campbell, 2012, Clinical Science). Angiotensin (1-9) addresses these pain points by offering a complementary mechanism that enhances the protective arm of the RAS without triggering the adverse effects associated with classical RAS inhibition.

Moreover, the emergence of ACE2 as a therapeutic target, particularly in the context of COVID-19, has renewed interest in angiotensin (1-9) as a modulator of vascular and pulmonary inflammation (Gheblawi et al., 2020, Circulation Research). By shifting the RAS balance towards vasoprotection and anti-inflammation, angiotensin (1-9) may mitigate the progression of acute and chronic organ injury.

Literature Review
A growing body of literature supports the therapeutic potential of angiotensin (1-9) in cardiovascular and renal diseases:

1. Ocaranza et al. (2010, Hypertension): In a rat model of myocardial infarction, chronic administration of angiotensin (1-9) reduced cardiac hypertrophy, fibrosis, and arrhythmias, with effects mediated via AT2R activation.

2. Ferreira et al. (2010, Peptides): This study demonstrated that angiotensin (1-9) induces vasorelaxation in isolated rat aorta, an effect abolished by AT2R antagonism, highlighting its endothelium-dependent mechanism.

3. Pinheiro et al. (2017, American Journal of Physiology-Renal Physiology): In diabetic rats, angiotensin (1-9) treatment attenuated renal injury, reduced proteinuria, and suppressed TGF-β expression, indicating renoprotective actions.

4. Ocaranza & Jalil (2012, Hypertension Research): The review summarizes the role of angiotensin (1-9) in cardiovascular remodeling, emphasizing its anti-fibrotic and anti-hypertrophic effects.

5. Campbell (2012, Clinical Science): This comprehensive review discusses the limitations of current RAS inhibitors and the therapeutic promise of targeting the ACE2/angiotensin (1-9)/AT2R axis.

6. Gheblawi et al. (2020, Circulation Research): The authors explore the relevance of ACE2 and its products, including angiotensin (1-9), in the pathophysiology of COVID-19 and associated cardiovascular complications.

7. Santos et al. (2013, Hypertension): This study elucidates the signaling pathways activated by angiotensin (1-9) and its role in counterbalancing angiotensin II-mediated effects.

[Related: beta nicotinamide mononucleotide] Experimental Data and Results
Preclinical studies have provided robust evidence for the efficacy of angiotensin (1-9) in various disease models:

- In a rat model of myocardial infarction, Ocaranza et al. (2010) administered angiotensin (1-9) (576 μg/kg/day, subcutaneously) for 28 days. Treated animals exhibited significant reductions in left ventricular hypertrophy, interstitial fibrosis, and arrhythmia incidence compared to controls. These effects were abrogated by AT2R antagonists, confirming receptor specificity.

- Ferreira et al. (2010) assessed the vasodilatory effects of angiotensin (1-9) in isolated rat aortic rings. Angiotensin (1-9) induced concentration-dependent relaxation, which was inhibited by endothelium removal and AT2R blockade, implicating NO-mediated signaling.

- Pinheiro et al. (2017) evaluated the renoprotective effects of angiotensin (1-9) in streptozotocin-induced diabetic rats. Chronic administration of angiotensin (1-9) (576 μg/kg/day) for 8 weeks resulted in reduced glomerulosclerosis, lower proteinuria, and decreased renal TGF-β expression.

- Additional studies have reported that angiotensin (1-9) modulates inflammatory cytokine production, reduces oxidative stress markers, and improves endothelial function in models of hypertension and metabolic syndrome (Ocaranza & Jalil, 2012; Santos et al., 2013).

Collectively, these data underscore the therapeutic promise of angiotensin (1-9) in attenuating pathological remodeling, preserving organ function, and modulating vascular tone.

Usage Guidelines and Best Practices
While angiotensin (1-9) is primarily utilized in preclinical research, several best practices have emerged for its experimental application:

- **Dosage and Administration:** In rodent models, effective doses range from 100 to 600 μg/kg/day, typically administered via subcutaneous or intravenous routes. Dose optimization should be guided by pharmacokinetic and pharmacodynamic profiling (Ocaranza et al., 2010; Pinheiro et al., 2017).

- **Formulation:** Angiotensin (1-9) is supplied as a synthetic peptide, with high purity (>95%) and stability under recommended storage conditions (-20°C, desiccated). Reconstitution in sterile saline or phosphate-buffered saline (PBS) is advised for in vivo and in vitro studies.

- **Controls:** Inclusion of appropriate controls, such as vehicle-treated and AT2R antagonist groups, is essential to delineate receptor-specific effects.

- **Endpoints:** Key experimental endpoints include assessment of organ function (e.g., echocardiography, renal function tests), histopathological analysis (fibrosis, hypertrophy), and molecular assays (NO, cGMP, TGF-β, cytokines).

- **Safety:** No significant adverse effects have been reported in animal studies at therapeutic doses. However, comprehensive toxicity and immunogenicity assessments are warranted prior to clinical translation.

Researchers are encouraged to adhere to institutional guidelines for animal experimentation and to report detailed methodologies for reproducibility.

[Related: bucladesine sodium] Future Research Directions
Despite promising pre Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 26 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11581775